No Data
No Data
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Hansa Biopharma AB (SE:HNSA)
Obesity Drugs Seen Costing Medicare $35 Billion Through 2034
Piper Sandler Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)
No Data
No Data